1. Development of peptoid-based heteroaryl-decorated histone deacetylase (HDAC) inhibitors with dual-stage antiplasmodial activity.
- Author
-
Stopper D, de Carvalho LP, de Souza ML, Kponomaizoun CE, Winzeler EA, Held J, and Hansen FK
- Subjects
- Humans, Structure-Activity Relationship, HEK293 Cells, Parasitic Sensitivity Tests, Molecular Structure, Dose-Response Relationship, Drug, Histone Deacetylases metabolism, Plasmodium falciparum drug effects, Plasmodium falciparum enzymology, Histone Deacetylase Inhibitors pharmacology, Histone Deacetylase Inhibitors chemistry, Histone Deacetylase Inhibitors chemical synthesis, Antimalarials pharmacology, Antimalarials chemistry, Antimalarials chemical synthesis, Peptoids pharmacology, Peptoids chemistry, Peptoids chemical synthesis
- Abstract
Dynamics of epigenetic modifications such as acetylation and deacetylation of histone proteins have been shown to be crucial for the life cycle development and survival of Plasmodium falciparum, the deadliest malaria parasite. In this study, we present a novel series of peptoid-based histone deacetylase (HDAC) inhibitors incorporating nitrogen-containing bicyclic heteroaryl residues as a new generation of antiplasmodial peptoid-based HDAC inhibitors. We synthesized the HDAC inhibitors by an efficient multicomponent protocol based on the Ugi four-component reaction. The subsequent screening of 16 compounds from our mini-library identified 6i as the most promising candidate, demonstrating potent activity against asexual blood-stage parasites (IC
50 Pf3D7 = 30 nM; IC50 PfDd2 = 98 nM), low submicromolar activity against liver-stage parasites (IC50 PbEEF = 0.25 μM), excellent microsomal stability (t1/2 > 60 min), and low cytotoxicity to HEK293 cells (IC50 = 136 μM)., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF